All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
HONG KONG – Clinical-stage biotech firm Athenex Inc. out-licensed to Chongqing Jingdong Junzhuo Pharmaceutical Co. Ltd. the rights to commercialize an ointment known as KX2-391 for treating actinic keratosis and oncology indications in China. Under the terms, Athenex will receive an up-front payment of $14.5 million and up to $15 million for development milestones. The company is also entitled to tiered royalties based on annual net sales starting at 15 percent, and with incremental increases of royalties with growing sales.